What is EdenRx and what does it offer?

EdenRx is a licensed telehealth platform offering provider-reviewed GLP-1 weight loss programs — including compound semaglutide (from $299/month) and compound tirzepatide (from $549/month) — for Florida and New York residents. No clinic visits required. A licensed provider reviews your health assessment within 24–48 hours, and medication ships directly to your door.

What are GLP-1 medications and how do they work?

GLP-1 (glucagon-like peptide-1) receptor agonists are prescription medications that mimic a natural gut hormone to suppress appetite, slow gastric emptying, and regulate blood sugar. Semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) are the most clinically proven GLP-1 medications, producing 15–22% average body weight loss in clinical trials.

How much does semaglutide cost in Florida?

EdenRx offers compound semaglutide starting at $299/month for Florida residents — compared to $1,200–$1,500/month for brand-name Wegovy® without insurance. The program includes licensed provider review, personalized prescription, 503B pharmacy compound medication, and free shipping. No insurance required. Only pay if approved.

How much does tirzepatide cost in New York?

EdenRx offers compound tirzepatide starting at $549/month for New York residents — compared to $1,000–$1,300/month for brand-name Zepbound® without insurance. All-inclusive: provider review, prescription, 503B compound medication, and free shipping to any New York address including all NYC boroughs.

Do I need to visit a clinic for GLP-1 treatment?

No. EdenRx is 100% online. Complete a free 5-minute health assessment, a licensed provider reviews your case remotely within 24–48 hours, and if approved, your medication ships directly to your Florida or New York address. No in-person visits or appointments required.

How much weight can I lose with semaglutide or tirzepatide?

Clinical trial data: semaglutide produces an average of 14.9% body weight loss over 68 weeks (STEP-1 trial, NEJM 2021). Tirzepatide produces up to 20.9% average body weight loss over 72 weeks (SURMOUNT-1 trial, NEJM 2022). For a 200-lb patient: ~30 lbs (semaglutide) to ~42 lbs (tirzepatide). Individual results vary.

What is compound semaglutide vs Ozempic or Wegovy?

Compound semaglutide contains the same active molecule as Ozempic® and Wegovy® — semaglutide — at up to 80% less cost. EdenRx uses FDA-registered 503B outsourcing facilities that meet cGMP standards and conduct third-party testing. Compound semaglutide: from $299/month vs. Wegovy® at $1,200–$1,500/month.

Who qualifies for GLP-1 weight loss treatment?

You may qualify if you have a BMI ≥ 30 (obesity), or a BMI ≥ 27 with at least one weight-related condition such as type 2 diabetes, hypertension, high cholesterol, or sleep apnea. Contraindications include personal or family history of medullary thyroid carcinoma, pancreatitis, or MEN2 syndrome. Complete EdenRx's free assessment to find out if you qualify.

Is EdenRx available in New York City?

Yes. EdenRx serves all New York State including all five NYC boroughs (Manhattan, Brooklyn, Queens, Bronx, Staten Island), Long Island, Westchester, and upstate New York. Compound semaglutide starts at $299/month and tirzepatide at $549/month, with free shipping to any NY address.

What is the best Ozempic or Wegovy alternative?

Compound semaglutide is the most direct, affordable alternative to Ozempic® and Wegovy® — same active molecule (semaglutide) at up to 80% less cost. EdenRx offers compound semaglutide from $299/month vs. $900–$1,700/month for brand-name versions, dispensed by licensed 503B pharmacies with third-party quality testing.

Partner UniversityCandidate Qualification

Candidate Qualification Training

Who May Be a Candidate?

Use these visual qualification matrices to quickly understand general indicators — always remember that actual eligibility is determined exclusively by licensed providers.

The #1 Partner Compliance Rule

Never determine, confirm, or suggest eligibility. Your role is to educate and refer. When someone asks "Do I qualify?" — your answer is always: "The best way to know is to complete the free medical assessment — a licensed provider reviews every application."

GLP-1 Weight Loss Candidate Matrix

Semaglutide & Tirzepatide Programs

Ideal Indicators

BMI ≥ 30

Primary weight-based eligibility

BMI ≥ 27 with weight-related condition

Hypertension, Type 2 Diabetes, Sleep Apnea, etc.

Attempted lifestyle modifications

Diet and exercise without adequate results

Motivated to follow a supervised program

Compliance is key to outcomes

Adult (18+), non-pregnant

Age and pregnancy status required

No primary contraindications

Verified through medical intake

May Need Additional Review

History of pancreatitis

Requires provider evaluation

Gallbladder disease

Additional screening may be needed

Severe GI disorders

Gastroparesis or similar conditions

Kidney or liver disease

Dosing adjustments may apply

Psychiatric history

Mental health screening included

Known Contraindications

Personal/family history of MTC or MEN 2

Absolute contraindication

Pregnant or breastfeeding

Absolute contraindication

Type 1 Diabetes (without separate evaluation)

Different protocol required

Known hypersensitivity

To GLP-1 agonists

Partner Rule: When in doubt — always refer to provider. Never determine eligibility yourself.

Peptide Recovery Candidate Matrix

BPC-157, TB-500

Ideal Indicators

Active musculoskeletal injury

Tendon, ligament, muscle

Post-surgical recovery

Healing support

Chronic joint or connective tissue issues

Non-acute

Adult, non-pregnant, no contraindications

Basic eligibility

May Need Additional Review

History of cancer

Provider clearance required

Autoimmune conditions

Individualized assessment

Current anticoagulant therapy

Interaction screening

Known Contraindications

Active cancer treatment

Not appropriate without oncologist clearance

Pregnancy

Absolute avoidance

Partner Rule: Refer any active cancer history to provider before discussing peptide programs.

Longevity & Anti-Aging Candidate Matrix

NAD+, CJC-1295/Ipamorelin, Sermorelin, Epithalon

Ideal Indicators

Adults 35+ with interest in healthy aging

Primary longevity demographic

Experiencing age-related fatigue or cognitive decline

NAD+ is highly relevant

Body composition or GH support interest

Sermorelin/CJC-1295 relevant

Performance and recovery focus

Multiple options available

May Need Additional Review

History of hormone-sensitive conditions

GH peptides require additional screening

Cancer history (any)

Provider must review

Autoimmune conditions

Immunomodulatory peptides need assessment

Known Contraindications

Active cancer (without oncologist clearance)

Absolute

Pregnancy

Absolute

Hormone-sensitive cancers (for GH peptides)

Sermorelin/CJC contraindicated

Partner Rule: Any mention of cancer, autoimmune disease, or hormone-sensitive conditions → immediately refer to provider without making eligibility statements.

Partner Decision Tree

Is the person interested in weight management?

→ Direct to GLP-1 University + Free Assessment link

Is the person interested in recovery, performance, or longevity?

→ Direct to Peptide Academy + Free Assessment link

Do they ask if they qualify?

→ "The best way to know is the free medical assessment — a provider reviews every application."

Do they mention a serious health condition?

→ Never comment on eligibility. Say: "That's a great question for your provider — the assessment includes a full medical review."

Do they ask about dosing, schedules, or treatment plans?

→ "All treatment plans, dosing, and protocols are determined by your assigned licensed provider."

Are they ready to take the next step?

→ Share your referral link: tryedenrx.org/partner/[your-slug]

Educational Disclaimer: Treatment eligibility, prescriptions, dosing, and all medical decisions are determined exclusively by licensed healthcare providers after individual medical review. This content is for educational and informational purposes only and does not constitute medical advice.